针对SARS-CoV-2的基于MultiTEP的疫苗尖端蛋白IgG位引起强大的结合抗体标位,具有有限的病毒中和活性
Tatevik Antonyan1, Garri Chilingaryan1, Karen Zagorski1
1Department of Molecular Immunology, The Institute for Molecular Medicine, Huntington Beach, CA 92647, USA.
Pathogens (Basel, Switzerland)
|June 26, 2024
概括
开发针对SARS-CoV-2等严重急性呼吸道贝塔冠状病毒的通用疫苗至关重要. 这项研究探讨了基于MultiTEP的COVID-19疫苗,这些疫苗产生了抗体,但在小鼠和非人类灵长类动物中缺乏中和活性.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 疫苗开发 疫苗开发
背景情况:
- 像SARS-CoV-2这样的严重急性呼吸道贝塔冠状病毒 (sarbecoviruses) 对公共健康构成重大威胁.
- SARS-CoV-2 的出现凸显了对抗呼吸道贝塔冠状病毒的广泛疫苗的迫切需要.
研究的目的:
- 使用MultiTEP通用疫苗平台开发和评估SARS-CoV-2表观型候选疫苗.
- 在临床前模型中评估基于MultiTEP的疫苗的免疫性和中和能力.
主要方法:
- 通过将片与MultiTEP序列融合,制造了18种SARS-CoV-2尖端蛋白表位疫苗.
- 小鼠用AdvaxCpG辅助剂配制的疫苗接种免疫,并通过ELISA和中和试验分析了抗体反应.
- 领先的疫苗候选人进一步在非人类灵长类动物 (NHPs) 中进行了测试.
主要成果:
- 所有基于MultiTEP的疫苗都在小鼠中诱导了高标位的结IgG抗体.
- 三种候选疫苗在替代中和试验中产生了抑制ACE2受体结合的抗体.
- 没有任何候选疫苗在小鼠或NHP中诱导对伪型病毒的中和抗体.
结论:
- 基于MultiTEP的COVID-19疫苗会引起针对SARS-CoV-2尖端蛋白的强烈IgG抗体反应.
- 目前的MultiTEP候选疫苗没有诱导中和抗体,这表明需要进一步完善广谱冠状病毒疫苗开发平台.
更多相关视频
相关概念视频
Cross-reactivity
31.0K
Overview
31.0K
Conjugated Proteins
18.3K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.3K
Antigens Involved in Adaptive Immunity
483
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
483


